ArticleBMC nephrology2026
Case report: delayed profound hypomagnesemia from carboplatin- associated renal magnesium wasting.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHypomagnesemia is a well-known side effect of certain chemotherapy drugs, especially platinum-based agents. Renal magnesium wasting is more frequent and better described with cisplatin. Carboplatin induced hypomagnesemia is common, generally mild, occurs during the treatment or shortly thereafter, and typically stabilizes or normalizes during follow up. CASE PRESENTATION: We report the case of a 58-year-old female patient with metastatic breast cancer, who presented for generalized pain and palpitations. Laboratory evaluation revealed severe hypomagnesemia due to renal magnesium wasting, one year after cessation of carboplatin therapy. A review of her other medications and other potential causes of hypomagnesemia did not identify additional contributors to magnesium wasting. Magnesium levels were normal before carboplatin initiation.
conclusionThis case highlights that renal magnesium wasting associated with carboplatin may rarely cause late profound hypomagnesemia, up to one year after treatment discontinuation. Therefore, magnesium levels need to be rigorously followed over long periods of time following carboplatin treatment even after initial reassuring levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.